Haptoglobin study in myasthenia gravis

Arquivos de Neuro-Psiquiatria

Volumn 66, Issue 2 A, 2008, Pages 229-233

  Mendonça Oliveira, Leonardo H ^a   França Jr , Marcondes C ^a   Nucci, Anamarli ^a,b   De Oliveira, Denise Madureira ^a   Kimura, Elza Myiuki ^a   Sonati, Maria De Fátima ^a,b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b Department of Neurology ^*

Author keywords

Acute phase response; Haptoglobin; Immune disorders; Myasthenia gravis

Indexed keywords

HAPTOGLOBIN;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL ARTICLE; CLINICAL PRACTICE; CLINICAL STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; GUILLAIN BARRE SYNDROME; HEALTH CARE ORGANIZATION; HEALTH STATUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LINEAR REGRESSION ANALYSIS; MALE; MYASTHENIA GRAVIS; PROTEIN ANALYSIS; REMISSION; SCORING SYSTEM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STUDENT T TEST; THYMECTOMY;

EID: 45849137398     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/S0004-282X2008000200017     Document Type: Article

References (16)

1. Sadrzadeh SMH, Bozorgmehr J. Haptoglobin phenotypes in health and disorders. Am J Clin Pathol 2004;121:97-104.
2. Melamed-Frank M, Lache O, Enav BI, et al. Structure-function analysis of the antioxidant properties of haptoglobin. Blood 2001;98:3693-3698.
3. Langlois MR, Delangue JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 1996;42:1589-1600.
4. Wobeto VPA, Rosim ET, Melo MB, Calliari LEP, Sonati MF. Haptoglobin polymorphism and diabetic retinopathy in Brazilian patients. Diab Res Clin Pract 2007;doi:10.1016/j.diabres.2006.12.018.
5. Panter SS, Sadrzadeh SMH, Hallaway PE, Haines JL, Anderson VE, Eaton JW. Hypohaptoglobinemia associated with familial epilepsy. J Exp Med 1985;161:748-754.
6. Saccucci P, Verdecchia M, Piciullo A, et al. Convulsive disorder and genetic polymorphism. Association of idiopathic generalized epilepsy with haptoglobin polymorphism. Neurogen 2004;5:245-248.
7. Borsody M, Burke A, Coplin W, Miller-Lotan R, Levy A. Haptoglobin and development of cerebral artery vasoespasm after subaracnoid hemorrhage. Neurology 2006;66: 634-640.
8. Gutowski NJ, Pinkham JM, Akanmu D, Chirico S, Murphy RP. Free radicals in inflamatory neurological disease: increased lipid peroxidation and haptoglobin levels in Guillain Barré syndrome. Ir J Med Sci 1998;167:43-46.
9. Lehmensiek V, Süssmuth SD, Brettschneider J, et al. Proteome analysis of cerebrospinal fluid in Guillain-Barré syndrome. J Neuroimmunol 2007;185:190-194.
10. Vicent A. Immunology of disorders of neuromuscular transmission. Acta Neurol Scand 2006;113:1-7.
11. Romi F, Gilhus NE, Aarli JA. Myasthenia gravis: clinical, immunological and therapeutic advances. Acta Neurol Scand 2005;111:134-141.
12. Zhang G, Navikas V, Link H. Cytokines and pathogenesis of myasthenia gravis. Muscle Nerve 1997;20:534-551.
13. Jaretki A, Barohn RJ, Ernstoff RM, et al. Myasthenia Gravis: recommendations for clinical research standards. Neurology 2000;55:16-23.
14. Tüzün E, Meriggioli MN, Rowin J, Yang H, Christadoss P. Myasthenia gravis patients with low plasma IL-6 and IFN-γ benefit from etanercept treatment. J Autoimmunity 2005;24:261-268.
15. Rowin J, Meriggioli MN, Tüzun E, Leurgans S, Christadoss P. Etanercept treatment in corticosteroid-dependent myasthenia gravis. Neurology 2004;63: 2390-2392.
16. Christensen PB, Jensen TS, Tsiropoulos I et al. Mortality and survival in myasthenia gravis: a Danish population based study. J Neurol Neurosurg Psychiatry 1998;64:78-83.